1. Volume 5, Issue 6, Pages 491-494 (June 2019)
Pembrolizumab for cutaneous squamous cell carcinoma: Report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation 
Mireille L.M. van Baar, MD, Alex D. Guminski, PhD, Peter M. Ferguson, PhD, Linda K. Martin, FACD 
JAAD Case Reports 
Volume 5, Issue 6, Pages (June 2019)
DOI: /j.jdcr
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

2. Fig 1
The pretreatment punch biopsy shows a moderately differentiated squamous cell carcinoma.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

3. Fig 2
Positron emission tomography scan shows multiple soft-tissue of fluoro-deoxy-glucose–avid deposits on the left leg.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

4. Fig 3
Clinical photograph immediately post-immunotherapy (left) and 12 months after immunotherapy (right): atrophic scarring 6 months after betamethasone dipropionate ointment under occlusion.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

5. Fig 4
Posttreatment with pembrolizumab. There is granulomatous inflammation in the dermis.
JAAD Case Reports 2019 5, DOI: ( /j.jdcr )
Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions